HRV Pharma, Haleos Labs partner to develop, manufacture orphan and niche APIs
HRV Pharma, Haleos Labs partner to develop, manufacture orphan and niche APIs
HRV Pharma and Haleos Labs have joined forces in a multi-year strategic partnership to fast-track the development and manufacturing of specialized active pharmaceutical ingredients (APIs) for rare diseases and niche therapies. This collaboration leverages HRV's global market access and Haleos' manufacturing expertise to introduce 5-7 new high-value molecules annually, targeting underserved patient populations worldwide.
HRV Pharma and Haleos Labs have joined forces in a multi-year strategic partnership to fast-track the development and manufacturing of specialized active pharmaceutical ingredients (APIs) for rare diseases and niche therapies. This collaboration leverages HRV's global market access and Haleos' manufacturing expertise to introduce 5-7 new high-value molecules annually, targeting underserved patient populations worldwide.
HRV Pharma and Haleos Labs have joined forces in a multi-year strategic partnership to fast-track the development and manufacturing of specialized active pharmaceutical ingredients (APIs) for rare diseases and niche therapies. This collaboration leverages HRV's global market access and Haleos' manufacturing expertise to introduce 5-7 new high-value molecules annually, targeting underserved patient populations worldwide. 
